Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS

Neurology: Neuroimmunology and NeuroInflammation

Volumn 5, Issue 3, 2018, Pages

  Makkawi, Seraj ^a,b   Camara Lemarroy, Carlos ^a   Metz, Luanne ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052824312     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000459     Document Type: Article

References (7)

1. Louie T, Adams PC. Nature's therapy for recurrent Clostridium difficile diarrhea. Can J Gastroenterol Hepatol 2008; 22: 455-456.
2. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 538-541.
3. Adamczyk-Sowa M, Medrek A, Madej P, Michlicka W, Dobrakowski P. Does the gut microbiota influence immunity and inflammation in multiple sclerosis pathophysiology? J Immunol Res 2017; 2017: 7904821.
4. Pröbstel AK, Baranzini SE. The role of the gut microbiome in multiple sclerosis risk and progression: towards characterization of the "MS microbiome". Neurotherapeutics 2018; 15: 126-134.
5. Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015; 21: 102-111.
6. Borody TJ, Leis SM, Campbell J, Torres M, Nowak A. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS) [abstract]. Am J Gastroenterol 2011; 106: S352.
7. Kremenchutzky M. Fecal microbial transplantation in relapsing multiple sclerosis patients. In: ClinicalTrials.gov [online]. Available at: clinicaltrials.gov/ct2/show/NCT03183869. Accessed February 2, 2018.